Bruker (BRKR)
(Delayed Data from NSDQ)
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Bruker (BRKR) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Outlook for Scientific Instruments Industry Looks Promising
by Zacks Equity Research
The Zacks Instruments - Scientific industry is benefiting from strong growth prospects in emerging markets, robust end-market demand and increasing spending on health care.
Bruker (BRKR) Q3 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
We are upbeat about Bruker's (BRKR) current focus on product development through higher R&D.
Bruker (BRKR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 23.33% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID
by Zacks Equity Research
Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.
Bruker (BRKR) Up 2.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) Q1 benefits from improved European revenues, rising year over year in high-single digits.
Is the Tax Repeal Only Glitter and No Gold for MedTech?
by Nabaparna Bhattacharya
While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.
Bruker (BRKR) Down 9.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Bruker (BRKR) registers organic revenue growth on strength in NANO and BEST platforms in Q4.
Cerner Gains Momentum in HCIT Space Amid Tough Competition
by Zacks Equity Research
Cerner (CERN) continues to benefit from the ongoing demand for its core solutions and services driven by the HITECH Act.
Abaxis Well Poised on Solid Prospects, Competition Rife
by Zacks Equity Research
Abaxis' (ABAX) new sales and marketing strategies boost investors' confidence.
Becton, Dickinson (BDX) a Step Closer to Bard Acquisition
by Zacks Equity Research
Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
The Zacks Analyst Blog Highlights: Bruker, Dana, Fair Isaac, Skechers and SodaStream
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bruker, Dana, Fair Isaac, Skechers and SodaStream
5 Strong Buy Stocks Gaining Momentum
by David Bartosiak
These five strong buy stocks are at highs and still gaining momentum
Zacks.com highlights: Natus Medical, GoPro, Enviva Partners and Bruker
by Zacks Equity Research
Zacks.com highlights: Natus Medical, GoPro, Enviva Partners and Bruker